Literature DB >> 2186744

Pathogenesis of the natural killer cell deficiency in AIDS.

M C Sirianni1, F Tagliaferri, F Aiuti.   

Abstract

Deficiency in natural killer (NK) cell activity is a common feature of acquired immune deficiency syndrome (AIDS). This is part of a general immune dysfunction in AIDS and may lead to progression of the disease, since NK cells are known to be involved in protection against tumors and against viral infections. The lack of immunological surveillance by NK cells of the growth of pathogens that activate the HIV-1 tat infectivity gene may also favor progression to AIDS. The pathogenesis of NK cell deficiency in AIDS is not known. Previous studies have shown that NK cells from AIDS patients are able to bind but not to lyse the target cell line K562. This results from an inability to rearrange the cytoskeleton microtubular (MT) system and to release the natural killer cytotoxic factor (NKCF). This report by Maria Caterina Sirianni and colleagues evaluates the possible mechanisms leading to this NK cell deficiency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186744     DOI: 10.1016/0167-5699(90)90032-5

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  15 in total

1.  Evaluation of natural killer cell activity.

Authors:  J H Cox; M deSouza
Journal:  Mol Biotechnol       Date:  2000-06       Impact factor: 2.695

2.  Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

Authors:  M P Nair; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

3.  Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals.

Authors:  M D Galiani; E Aguado; R Tarazona; P Romero; I Molina; M Santamaria; R Solana; J Peña
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

4.  Effects of ultraviolet irradiation on natural killer cell function in systemic lupus erythematosus.

Authors:  O Nived; I Johansson; G Sturfelt
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

5.  Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy.

Authors:  Antonio Valentin; Margherita Rosati; Daniel J Patenaude; Angelos Hatzakis; Leondios G Kostrikis; Marios Lazanas; Kathleen M Wyvill; Robert Yarchoan; George N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

6.  Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone.

Authors:  M R Goodier; N Imami; G Moyle; B Gazzard; F Gotch
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

7.  Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands.

Authors:  Jeffrey A Martinson; Alejandro Roman-Gonzalez; Allan R Tenorio; Carlos J Montoya; Carolyne N Gichinga; Maria T Rugeles; Mark Tomai; Arthur M Krieg; Smita Ghanekar; Linda L Baum; Alan L Landay
Journal:  Cell Immunol       Date:  2008-03-10       Impact factor: 4.868

8.  Natural killer (NK) cell activity during HIV infection: a decrease in NK activity is observed at the clonal level and is not restored after in vitro long-term culture of NK cells.

Authors:  D Scott-Algara; F Vuillier; A Cayota; G Dighiero
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

9.  Effects of simulated microgravity on primary human NK cells.

Authors:  Qi Li; Qibing Mei; Ting Huyan; Li Xie; Su Che; Hui Yang; Mingjie Zhang; Qingsheng Huang
Journal:  Astrobiology       Date:  2013-08-06       Impact factor: 4.335

10.  Effects of stress management on PNI-based outcomes in persons with HIV disease.

Authors:  Nancy L McCain; Barbara A Munjas; Cindy L Munro; R K Elswick; Jo L Wheeler Robins; Andrea Ferreira-Gonzalez; Beverly Baliko; Lisa G Kaplowitz; Evelyn J Fisher; Carleton T Garrett; Kevin E Brigle; Linda C Kendall; Valentina Lucas; Katherine L Cochran
Journal:  Res Nurs Health       Date:  2003-04       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.